Pharmacokinetics and Safety of TIN816 in Patients With Sepsis-associated Acute Kidney Injury

A Participant and Investigator-blinded, Randomized, Placebo-controlled Phase 2a Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of TIN816 in Patients With Sepsis-associated Acute Kidney Injury

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05507437

Enrollment

Registered

2022-08-19

Start date

2022-11-22

Completion date

2024-04-25

Last updated

2025-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury Due to Sepsis

Keywords

Sepsis, acute kidney injury, intensive care, therapy

Brief summary

The purpose of this study was to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profile and to evaluate the safety and tolerability of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis-associated acute kidney injury (SA-AKI).

Detailed description

This was a multicenter, participant and investigator-blinded, randomized, placebo-controlled study to characterize PK/PD profile and to evaluate the safety and the tolerability of TIN816. The study enrolled hospitalized adult participants with a diagnosis of sepsis and acute kidney injury (AKI). 20 participants were randomized in the study. The study consisted of a screening period (24-48 hours), a treatment period (day 1), and post-treatment period (days 2 to 90). Screening took place during hospitalization in a intensive care unit (ICU) (or intermediate/high dependency unit (HDU care) where potential participants were undergo screening to assess the presence of sepsis and AKI. Pre-identified participants provided informed consent and went to screening assessments to determine eligibility. Potential study candidates were hospitalized patients with a diagnosis of sepsis based on Sepsis 3 criteria with suspected or confirmed infection and SOFA score ≥ 2 after excluding the renal component, and a diagnosis of AKI stage 1 or greater. At Treatment Day 1, participants who meet eligibility criteria at screening and baseline were randomized in a 3:1 ratio to treatment with TIN816 or placebo by intravenous infusion in a participant and investigator-blinded fashion. Treatment day 1 was followed by a 90 day post-treatment period for pharmocokinetic, pharmacodynamic, safety and tolerability assessments.

Interventions

BIOLOGICALTIN816 70 mg lyophilisate powder

Recombinant human CD39 enzyme

OTHERPlacebo

0.9% sterile sodium chloride solution

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

1. Signed informed consent must be obtained prior to participation in the study. 2. ≥ 18 and ≤ 85 years of age. 3. Admitted to ICU or intermediate/HDU. 4. Diagnosis of sepsis according to criteria defined by The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) based on: Suspected or confirmed infection SOFA score of 2 or more (excluding renal component) 5. Diagnosis of AKI Stage 1 or greater per the following criterion at randomization : An absolute increase in serum or plasma creatinine (CR) by ≥0.3 mg/dL (≥26.5 µmol/L) within 48 hours or presumed to have occurred in the previous 48 hours as compared to the reference creatinine baseline. For hospital-acquired AKI, a stable serum creatinine obtained in the hospital prior to AKI should be used as reference baseline, otherwise, baseline serum creatinine in the following order of preference: Median value within 3 months of the hospital admission. If not available: Median value between 3 and 6 months prior to hospital admission. If not available: At hospital admission.

Exclusion criteria

1. Not expected to survive for 24 hours. 2. Not expected to survive for 30 days due to medical conditions other than SA-AKI. 3. History of CKD with a documented estimated GFR \<45 ml/min prior to development of AKI. 4. Receiving RRT or a decision has been made to initiate RRT within 24 hours of admission. 5. Weight is less than 40 kg or more than 125 kg . 6. Has life support limitations (eg, do not resuscitate, do not dialyze, do not intubate). 7. AKI diagnosis according to the AKI inclusion criteria for a period longer than 48 hours prior to study drug administration. 8. Presence of AKI for a period longer than 48 hours prior to study drug administration as suggested by clinical manifestations, e.g., prolonged oliguria or severe renal dysfunction (eg, serum creatinine \> 4 mg/dL) on admission without a history of CKD. 9. Evidence of recovery from AKI based on the investigator's clinical judgement prior to randomization. 10. AKI is most likely attributable to causes other than sepsis such as nephrotoxic drugs (Non-steroidal anti-inflammatory drugs (NSAIDs), contrast, aminoglycosides), other medical conditions (e.g. heart failure, liver failure, acute abdominal aortic aneurysm, dissection, renal artery stenosis) or urinary obstruction. 11. Documented (biopsy proven) or suspected history of acute or sub-acute kidney diseases such as rapidly progressive glomerular nephritis (RPGN) and acute interstitial nephritis (AIN). 12. Patients who are post-nephrectomy. 13. Patients who are on dual antiplatelet therapy. 14. Patients who are thrombocytopenic at screening (Platelet count \<100,000 microliter) or other high risk for bleeding in the opinion of the investigator. 15. Immunosuppressed patients: History of immunodeficiency diseases or known HIV test positive. Is receiving immunosuppressant treatment or is on chronic high doses (high-dose therapy exceeding 2 weeks of treatment) of steroids equivalent to prednisone/prednisolone 0.5 mg/kg/day, including solid organ transplant patients. Patients with septic shock treated with hydrocortisone (e.g., 3 × 100 mg) can be included. 16. Active hepatitis (defined as (a) abnormal liver enzymes (Alanine aminotransferase (ALT), Gamma-glutamyl transferase (GGT), ALP \> 3x Upper Limit of Normal (ULN) or (b)) for active hepatitis B or C infection, a positive Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) serology or patients with advanced chronic liver disease, confirmed by a Child-Pugh score of 10-15 (Class C). 17. Acute pancreatitis with no established source of infection. 18. Active hematological malignancy (previous hematological malignancies that are not actively treated are allowable). 19. Burns requiring ICU treatment. 20. Sepsis attributed to confirmed COVID-19. 21. Use of other investigational drugs within 5 half-lives of enrollment within 30 days (e.g., small molecules) / or until the expected pharmacodynamic effect has returned to baseline (e.g., biologics), whichever is longer; or longer if required by local regulations. 22. History of hypersensitivity to the study treatment or its excipients or to drugs of similar chemical classes. 23. Any medical conditions that could significantly increase risk of participants' safety by participating in this study according to investigator's judgement. 24. Women with a positive pregnancy test, pregnancy or breast feeding. 25. Women of child-bearing potential

Design outcomes

Primary

Measure	Time frame	Description
The Apparent Volume of Distribution (Vz) of TIN816	Day 1 (Pre-dose and 2 hours), Day 2, Day 3, Day 5, Day 8, Day 14, Day 30, Day 60 and Day 90	Vz is the apparent volume of distribution during terminal phase following intravenous administration. TIN816 serum concentrations were determined using the actual recorded sampling times and non-compartmental method with Phoenix WinNonlin (Version 8.3). TIN816 concentrations were determined by a validated ligand binding assay with a lower limit of quantification (LLOQ) of 10 ng/mL.
Maximum Serum Concentration (Cmax) of TIN816	Day 1 (Pre-dose and 2 hours), Day 2, Day 3, Day 5, Day 8, Day 14, Day 30, Day 60 and Day 90	Cmax is defined as the maximum (peak) observed concentration following a dose. TIN816 serum concentrations were determined using the actual recorded sampling times and non-compartmental method with Phoenix WinNonlin (Version 8.3). TIN816 concentrations were determined by a validated ligand binding assay with a lower limit of quantification (LLOQ) of 10 ng/mL.
Area Under Serum Concentration-time Curve From Time Zero to the Last Measurable Concentration Sampling Time (AUClast) of TIN816	Day 1 (Pre-dose and 2 hours), Day 2, Day 3, Day 5, Day 8, Day 14, Day 30, Day 60 and Day 90	AUClast is the area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (tlast) of TIN816. TIN816 serum concentrations were determined using the actual recorded sampling times and non-compartmental method with Phoenix WinNonlin (Version 8.3). TIN816 concentrations were determined by a validated ligand binding assay with a lower limit of quantification (LLOQ) of 10 ng/mL.
Area Under the Serum Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0-inf]) of TIN816	Day 1 (Pre-dose and 2 hours), Day 2, Day 3, Day 5, Day 8, Day 14, Day 30, Day 60 and Day 90	The AUC from time zero to infinity (mass x time x volume-1). TIN816 serum concentrations were determined using the actual recorded sampling times and non-compartmental method with Phoenix WinNonlin (Version 8.3). TIN816 concentrations were determined by a validated ligand binding assay with a lower limit of quantification (LLOQ) of 10 ng/mL.
Time to Reach Maximum Serum Concentration (Tmax) of TIN816	Day 1 (Pre-dose and 2 hours), Day 2, Day 3, Day 5, Day 8, Day 14, Day 30, Day 60 and Day 90	Tmax is the time to reach maximum (peak) drug concentration after single-dose administration (time). TIN816 serum concentrations were determined using the actual recorded sampling times and non-compartmental method with Phoenix WinNonlin (Version 8.3). TIN816 concentrations were determined by a validated ligand binding assay with a lower limit of quantification (LLOQ) of 10 ng/mL.
Terminal Elimination Half-life (T1/2) of TIN816	Day 1 (Pre-dose and 2 hours), Day 2, Day 3, Day 5, Day 8, Day 14, Day 30, Day 60 and Day 90	T1/2 is the elimination half-life associated with the terminal slope. TIN816 serum concentrations were determined using the actual recorded sampling times and non-compartmental method with Phoenix WinNonlin (Version 8.3). TIN816 concentrations were determined by a validated ligand binding assay with a lower limit of quantification (LLOQ) of 10 ng/mL.
Total Body Clearance (CL) of TIN816	Day 1 (Pre-dose and 2 hours), Day 2, Day 3, Day 5, Day 8, Day 14, Day 30, Day 60 and Day 90	CL is the total body clearance of TIN816 from the serum following intravenous administration (volume x time-1). TIN816 serum concentrations were determined using the actual recorded sampling times and non-compartmental method with Phoenix WinNonlin (Version 8.3). TIN816 concentrations were determined by a validated ligand binding assay with a lower limit of quantification (LLOQ) of 10 ng/mL.

Secondary

Measure	Time frame	Description
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)	Adverse events were reported from first dose of study treatment until end of study treatment plus follow up period, up to a maximum duration of approximately 90 days.	Number of participants with treatment emergent AEs (any AE regardless of seriousness) and SAEs.

Countries

Belgium, France, Germany, Hungary, Spain

Participant flow

Recruitment details

Participants took part in 7 investigative sites in 5 countries.

Pre-assignment details

The study consisted of a screening period up to 48 hours.

Participants by arm

Arm	Count
TIN816 TIN816 2 mg/kg intravenous dose on Day 1.	16
Placebo Placebo intravenous dose on Day 1	4
Total	20

Withdrawals & dropouts

Period	Reason	FG000	FG001
Overall Study	Death	3	0
Overall Study	Withdrawal by Subject	1	1

Baseline characteristics

Characteristic	TIN816	Placebo	Total
Age, Continuous	66.25 years STANDARD_DEVIATION 12.25	68.0 years STANDARD_DEVIATION 19.95	66.60 years STANDARD_DEVIATION 13.484
Race/Ethnicity, Customized Not Reported	14 Participants	3 Participants	17 Participants
Race/Ethnicity, Customized White	2 Participants	1 Participants	3 Participants
Sex: Female, Male Female	3 Participants	1 Participants	4 Participants
Sex: Female, Male Male	13 Participants	3 Participants	16 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk
deaths Total, all-cause mortality	3 / 16	0 / 4	3 / 20
other Total, other adverse events	14 / 16	4 / 4	18 / 20
serious Total, serious adverse events	11 / 16	1 / 4	12 / 20

Outcome results

Primary

Area Under Serum Concentration-time Curve From Time Zero to the Last Measurable Concentration Sampling Time (AUClast) of TIN816

AUClast is the area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (tlast) of TIN816. TIN816 serum concentrations were determined using the actual recorded sampling times and non-compartmental method with Phoenix WinNonlin (Version 8.3). TIN816 concentrations were determined by a validated ligand binding assay with a lower limit of quantification (LLOQ) of 10 ng/mL.